Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) FCF Margin (2016 - 2025)

IGC Pharma has reported FCF Margin over the past 16 years, most recently at 1109.42% for Q3 2025.

  • Quarterly FCF Margin fell 86064.0% to 1109.42% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 508.68% through Sep 2025, down 8510.0% year-over-year, with the annual reading at 386.07% for FY2025, 1073.0% up from the prior year.
  • FCF Margin was 1109.42% for Q3 2025 at IGC Pharma, down from 431.4% in the prior quarter.
  • Over five years, FCF Margin peaked at 183.39% in Q1 2024 and troughed at 4167.86% in Q3 2021.
  • The 5-year median for FCF Margin is 671.69% (2022), against an average of 1092.77%.
  • The largest YoY upside for FCF Margin was 613201bps in 2021 against a maximum downside of -197026bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 1724.65% in 2021, then surged by 61bps to 671.69% in 2022, then decreased by -21bps to 811.27% in 2023, then skyrocketed by 36bps to 522.96% in 2024, then plummeted by -112bps to 1109.42% in 2025.
  • Per Business Quant, the three most recent readings for IGC's FCF Margin are 1109.42% (Q3 2025), 431.4% (Q2 2025), and 226.67% (Q1 2025).